文献速递术前评估与围术期医学疼痛医学

右美托咪定超前镇痛对非心脏手术术中及术后疼痛的影响:随机双盲对照研究

Dexmedetomidine Preemptive Analgesia on Intra- and Postoperative Pain in Noncardiac Surgery: A Randomized, Double-Blind, Controlled Study.
PubMed 文献 · Anesth Analg · 2026-05-28

该单中心双盲随机对照试验纳入220例非心脏手术患者,比较右美托咪定(DEX)与安慰剂超前镇痛的效果。DEX组术中伤害性刺激指数(NOX)达标率显著更高,术后各时间点中重度疼痛发生率显著更低,且减少阿片类补救用量和术后恶心呕吐。

要点

  • 右美托咪定超前镇痛显著提高术中NOX达标率(90.7% vs 12.5%)。
  • DEX组术后各时间点中重度疼痛发生率均显著低于安慰剂组。
  • DEX减少阿片类补救用量和术后恶心呕吐,血流动力学更稳定。

核心结论

  • 右美托咪定超前镇痛显著改善术中伤害性控制(NOX客观监测)和术后疼痛控制,优化围术期镇痛并促进康复。

研究设计与样本

  • 单中心、双盲、随机对照试验,纳入220例非心脏手术患者,随机接受右美托咪定(1.5 µg·kg⁻¹·h⁻¹)或安慰剂(生理盐水),从麻醉诱导前15分钟至诱导后15分钟给药。

主要发现

  • DEX组术中NOX达标率(平均NOX≤60)为90.7%(98/108),显著高于安慰剂组的12.5%(14/112),P < .001。
  • 术后0小时中重度疼痛(pNRS>3)发生率DEX组2.8%(3/108)vs 安慰剂组25.9%(29/112);24小时5.6%(6/108)vs 29.5%(33/112);48小时0.9%(1/108)vs 17%(19/112);7天0%(0/108)vs 5.4%(6/112),P = .000。
  • DEX组阿片类补救用量减少(z = -2.428,P = .004),术后恶心呕吐减少(z = -4.901,P = .001),血流动力学更稳定,安全性良好。

临床怎么用

  • 对于非心脏手术患者,可考虑在麻醉诱导前15分钟至诱导后15分钟静脉输注右美托咪定1.5 µg·kg⁻¹·h⁻¹,以改善术中伤害性控制和术后镇痛。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inadequate pain management affects over half of the 230 million major surgeries performed annually. Preemptive analgesia aims to prevent peripheral and central sensitization. Dexmedetomidine (DEX) offers non-opioid analgesia and opioid-sparing effects. This study evaluated the efficacy of preemptive DEX using the nociception index (NOX) for objective intraoperative monitoring and assessed its impact on perioperative outcomes. METHODS: In this single-center, double-blind, randomized controlled trial, 220 eligible patients were assigned to receive either intravenous DEX (1.5 µg·kg -1 ·h -1 ) (DEX group) or placebo (normal saline) (PO group) from 15 minutes before anesthesia induction until 15 minutes post-induction. The co-primary outcomes were the intraoperative NOX compliance rate (mean NOX ≤60 during nociceptive stimulation) and the incidence of moderate-to-severe postoperative pain (pNRS > 3) at 0, 24, 48 hours, and 7 days. Secondary outcomes included hemodynamic parameters, postoperative nausea and vomiting (mPONV), dizziness, analgesic consumption, and safety events. RESULTS: The DEX group demonstrated a significantly higher NOX compliance rate compared to the placebo group (98/108, 90.7% vs 14/112, 12.5%; P < .001). The incidence of NRS>3 was significantly lower in the DEX group at all postoperative time points (3/108, 2.8% vs 29/112, 25.9% at 0 hour; 6/108, 5.6% vs 33/112, 29.5% at 24 hours; 1/108, 0.9% vs 19/112, 17% at 48 hours; 0/108, 0% vs 6/112, 5.4% at 7 d; P = .000). DEX also reduced rescue opioid consumption ( z = -2.428, P = .004), decreased mPONV ( z = -4.901, P = .001), and improved hemodynamic stability. Safety profiles were favorable in DEX group. CONCLUSION: Preemptive analgesia with DEX significantly improves both intraoperative nociceptive control as objectively measured by the NOX and postoperative pain control. It validates the role in optimizing perioperative analgesia and enhancing recovery.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Wang X, Chang H, Qi W, et al. Dexmedetomidine Preemptive Analgesia on Intra- and Postoperative Pain in Noncardiac Surgery: A Randomized, Double-Blind, Controlled Study. Anesth Analg. 2026. PMID: 42207991. doi:10.1213/ANE.0000000000008078

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。